Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pertuzumab + trastuzumab + vinorelbine
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of two HER2-targeted monoclonal antibodies (pertuzumab and trastuzumab) plus vinorelbine, a vinca alkaloid chemotherapy agent. This regimen provides comprehensive HER2 blockade through the complementary mechanisms of pertuzumab and trastuzumab, while vinorelbine offers an alternative chemotherapy partner to docetaxel. It is primarily used for the treatment of HER2-positive locally advanced or metastatic breast cancer, particularly for patients who cannot receive or prefer not to receive docetaxel.
- Brand names
- KanjintiPerjetaNavelbine
- Other names
- Kanjinti plus Pertuzumab plus VinorelbineTrastuzumab biosimilar plus Pertuzumab plus VinorelbineVinorelbine-based triple combination
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on pertuzumab + trastuzumab + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pertuzumab + trastuzumab + vinorelbine.